SCHEMBL19793237

SCHEMBL19793237

O=C1CCCC(O)N1CCC1CCCCN1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 2/20 0.38
KMT2A Q03164 3/20 0.35
CYP2D6 P10635 2/20 0.34
MEN1 O00255 2/20 0.34
LMNA P02545 2/20 0.34
TP53 P04637 2/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
TSHR P16473 1/20 0.34
MLNR O43193 1/20 0.34
ABCB11 O95342 1/20 0.34
EGFR P00533 1/20 0.34
FYN P06241 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
HTR1A P08908 1/20 0.34
CHRM5 P08912 1/20 0.34
ADRA2A P08913 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
CHRM1 P11229 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19793297 0.96 FDPS (0.33) FDPSKMT2A
SCHEMBL17525713 0.77 HRH3 (0.41) FDPSKMT2ACYP2D6MEN1LMNA
SCHEMBL17525467 0.72 KMT2A (0.38) FDPSKMT2AMEN1HTR1AHRH3
SCHEMBL5414432 0.70 KMT2A (0.35) FDPSKMT2ACYP2D6CYP1A2HTR1A
SCHEMBL19793340 0.70 CYP1A2 (0.41) TP53CYP1A2ADRA2A
SCHEMBL5394447 0.69 KMT2A (0.33) FDPSKMT2AHRH3PRKACAPRKACG
SCHEMBL5394423 0.68 KMT2A (0.33) KMT2AHRH3PRKACAPRKACGPRKACB
SCHEMBL891139 0.66
SCHEMBL1010137 0.66
SCHEMBL214440 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10196377-B2 Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” (RU) 2019-02-05 US disclosed
US-20180022728-A1 Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) 2018-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180022728-A1 Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives GCDH, GLS, HADH FDPS 535/4885KMT2A 2594/4885CYP2D6 147/4885
US-10196377-B2 Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives GCDH, GLS, HADH FDPS 534/4885KMT2A 2520/4885CYP2D6 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.